All infants younger than 8 months who are born during – or entering – their first RSV season should receive one dose of nirsevimab. However, immune protection will wane over time. It is long-acting, providing protection for at least 5 months (the average length of one season), and only one dose is recommended for an RSV season. It is administered by intramuscular injection. Nirsevimab (Beyfortus) is a monoclonal antibody product designed to protect infants and young children at increased risk from severe RSV disease. Monoclonal Antibody Products for Infants and Young Children Studies are ongoing to determine whether (and if so, when) revaccination may be needed. RSV vaccine is recommended as a single dose. Healthcare providers should be aware of underlying conditions that may increase the risk of severe RSV illness, and who might be most likely to benefit from these new vaccines. It may be informed by the patient’s risk of severe RSV disease and their characteristics, values, and preferences the healthcare provider’s clinical discretion and the characteristics of the vaccine. The decision to vaccinate an individual patient should be based on a discussion between the healthcare provider and the patient. CDC recommends that adults 60 and older may receive an RSV vaccine, using shared clinical decision-making. New vaccines against RSV are available for adults 60 and older. A healthcare provider’s recommendation is one of the most important factors in whether patients choose to accept a new prevention product or vaccine. Monoclonal antibody products are available to protect infants and young children from severe RSV. RSV Vaccines are available to protect older adults from severe RSV. For more information about recommended infection prevention and control practices in healthcare settings, see CDC’s 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Healthcare providers should consider RSV in patients with respiratory illness, particularly during the RSV season. In most regions of the United States, RSV season starts in the fall and peaks in the winter, but the timing and severity of RSV season in a given community can vary from year to year. It causes annual outbreaks of respiratory illnesses in all age groups. Respiratory syncytial virus (RSV) is recognized as one of the most common causes of childhood illness and is the most common cause of hospitalization in infants.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |